Connect Biopharma Holdings
CNTB
28 hedge funds and large institutions have $53.4M invested in Connect Biopharma Holdings in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 10 closing their positions.
140% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 5
1.29% more ownership
Funds ownership: 29.51% → 30.8% (+1.3%)
3% less funds holding
Funds holding: 29 → 28 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
39% less capital invested
Capital invested by funds: $87.4M → $53.4M (-$34M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $32K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$4.96M |
| 2 |
SCM
Sio Capital Management
New York
|
+$2.52M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.75M |
| 4 |
Barclays
London,
United Kingdom
|
+$1.32M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$961K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.79M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$3.33M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.03M |
| 4 |
ACM
Altium Capital Management
New York
|
-$901K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$634K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Simplex Trading
Chicago,
Illinois
| $3K | -$29.5K | -6,977 | -85% |
|
27
Citigroup
New York
| $3K | -$8.06K | -1,910 | -64% |
|
|
DTC
28
Deep Track Capital
Greenwich,
Connecticut
| – | -$3.33M | -647,057 | Closed |
|
|
CAM
29
Cormorant Asset Management
Boston,
Massachusetts
| – | -$1.03M | -200,000 | Closed |
|
|
ACM
30
Altium Capital Management
New York
| – | -$901K | -175,000 | Closed |
|
|
31
Marshall Wace
London,
United Kingdom
| – | -$634K | -123,109 | Closed |
|
|
DAM
32
DLD Asset Management
New York
| – | -$627K | -121,707 | Closed |
|
33
Ensign Peak Advisors
Salt Lake City,
Utah
| – | -$131K | -25,412 | Closed |
|
34
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$68.4K | -16,212 | Closed |
|
35
Two Sigma Investments
New York
| – | -$81K | -15,632 | Closed |
|
36
Citadel Advisors
Miami,
Florida
| – | -$79K | -15,273 | Closed |
|
37
Wells Fargo
San Francisco,
California
| – | +$13 | +3 | New |
|
CNTB Hedge Fund Activity: Q1 2022 in Review
28 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Connect Biopharma Holdings (CNTB) for Q1 2022, worth a combined $53.4M — down 39% from $87.4M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CNTB and 9 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 12 added.
The largest buyer was Janus Henderson Group, adding an estimated $4.96M. The largest seller was Fidelity Investments, cutting an estimated $4.79M.
- 28 institutional investors held Connect Biopharma Holdings (CNTB) as of Q1 2022, down from 29 in Q4 2021.
- Funds reported $53.4M of Connect Biopharma Holdings stock for Q1 2022, down 39% quarter-over-quarter.
- 9 funds opened new Connect Biopharma Holdings positions in Q1 2022 and 10 closed out, a net change of -1 holder.
- The largest Connect Biopharma Holdings buyer in Q1 2022 was Janus Henderson Group, an estimated $4.96M added.
- The largest Connect Biopharma Holdings seller in Q1 2022 was Fidelity Investments, an estimated $4.79M sold.
Based on aggregated 13F filings for Q1 2022.